Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes

Francesco Colotta, Simona Saccani, Judith G. Giri, Steven K. Dower, John E. Sims, Martino Introna, Alberto Mantovani

Research output: Contribution to journalArticle

Abstract

The aim of this study was to investigate the expression and release of the IL-1 type II decoy receptor (R) in mononuclear phagocytes, which play a central role in immune and chronic inflammatory reactions. Human monocytes expressed both type I and type II R transcripts, the latter being two- to threefold more represented. By cross-linking and Ab blocking, the predominant surface IL-1-binding molecule was the decoy RII. IL-4, IL-13, and dexamethasone induced RI and RII transcripts and augmented the number of IL- 1-binding sites with no modification of K(d) values. The induced surface receptor was identified as the decoy RII. These stimuli induced the release of a soluble R with a m.w. of approximately 60 kDa, of which N-glycosylation contributed 22 kDa compared with 45 kDa released from polymorphonuclear leukocytes, of which N-glycosylation contributed 15 kDa. IL-13 and dexamethasone induced a release of 24 ng/ml/2 x 107 cells (from 8.7 to 43.2 ng/ml) and 25.6 ng/ml/2 x 107 cells (from 9.7 to 36.8 ng/ml) of decoy RII in 18 h, respectively (six donors). Thus, for instance, IL-13-treated (18 h) cells expressed 3.5 x 103 sites/cell and released 12 x 103 decoy RII/cell. The released decoy RII from monocytes bound IL-1α and IL-1 receptor antagonist 30- and 2-fold less avidly than IL-1β, respectively. In vitro- matured, monocyte-derived macrophages showed higher levels of surface expression and release of the IL-1 decoy RII. The results show that, on exposure to diverse molecules with anti-inflammatory properties, mononuclear phagocytes express and release copious amounts of a novel version of the soluble IL-1 decoy RII.

Original languageEnglish
Pages (from-to)2534-2541
Number of pages8
JournalJournal of Immunology
Volume156
Issue number7
Publication statusPublished - Apr 1 1996

Fingerprint

Interleukin-1 Receptors
Phagocytes
Interleukin-1
Interleukin-13
Glycosylation
Dexamethasone
Monocytes
Interleukin-4
Neutrophils
Anti-Inflammatory Agents
Macrophages
Binding Sites

ASJC Scopus subject areas

  • Immunology

Cite this

Colotta, F., Saccani, S., Giri, J. G., Dower, S. K., Sims, J. E., Introna, M., & Mantovani, A. (1996). Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. Journal of Immunology, 156(7), 2534-2541.

Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. / Colotta, Francesco; Saccani, Simona; Giri, Judith G.; Dower, Steven K.; Sims, John E.; Introna, Martino; Mantovani, Alberto.

In: Journal of Immunology, Vol. 156, No. 7, 01.04.1996, p. 2534-2541.

Research output: Contribution to journalArticle

Colotta, F, Saccani, S, Giri, JG, Dower, SK, Sims, JE, Introna, M & Mantovani, A 1996, 'Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes', Journal of Immunology, vol. 156, no. 7, pp. 2534-2541.
Colotta F, Saccani S, Giri JG, Dower SK, Sims JE, Introna M et al. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. Journal of Immunology. 1996 Apr 1;156(7):2534-2541.
Colotta, Francesco ; Saccani, Simona ; Giri, Judith G. ; Dower, Steven K. ; Sims, John E. ; Introna, Martino ; Mantovani, Alberto. / Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. In: Journal of Immunology. 1996 ; Vol. 156, No. 7. pp. 2534-2541.
@article{f622d9e4341845babe6f558820f5f90d,
title = "Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes",
abstract = "The aim of this study was to investigate the expression and release of the IL-1 type II decoy receptor (R) in mononuclear phagocytes, which play a central role in immune and chronic inflammatory reactions. Human monocytes expressed both type I and type II R transcripts, the latter being two- to threefold more represented. By cross-linking and Ab blocking, the predominant surface IL-1-binding molecule was the decoy RII. IL-4, IL-13, and dexamethasone induced RI and RII transcripts and augmented the number of IL- 1-binding sites with no modification of K(d) values. The induced surface receptor was identified as the decoy RII. These stimuli induced the release of a soluble R with a m.w. of approximately 60 kDa, of which N-glycosylation contributed 22 kDa compared with 45 kDa released from polymorphonuclear leukocytes, of which N-glycosylation contributed 15 kDa. IL-13 and dexamethasone induced a release of 24 ng/ml/2 x 107 cells (from 8.7 to 43.2 ng/ml) and 25.6 ng/ml/2 x 107 cells (from 9.7 to 36.8 ng/ml) of decoy RII in 18 h, respectively (six donors). Thus, for instance, IL-13-treated (18 h) cells expressed 3.5 x 103 sites/cell and released 12 x 103 decoy RII/cell. The released decoy RII from monocytes bound IL-1α and IL-1 receptor antagonist 30- and 2-fold less avidly than IL-1β, respectively. In vitro- matured, monocyte-derived macrophages showed higher levels of surface expression and release of the IL-1 decoy RII. The results show that, on exposure to diverse molecules with anti-inflammatory properties, mononuclear phagocytes express and release copious amounts of a novel version of the soluble IL-1 decoy RII.",
author = "Francesco Colotta and Simona Saccani and Giri, {Judith G.} and Dower, {Steven K.} and Sims, {John E.} and Martino Introna and Alberto Mantovani",
year = "1996",
month = "4",
day = "1",
language = "English",
volume = "156",
pages = "2534--2541",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "7",

}

TY - JOUR

T1 - Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes

AU - Colotta, Francesco

AU - Saccani, Simona

AU - Giri, Judith G.

AU - Dower, Steven K.

AU - Sims, John E.

AU - Introna, Martino

AU - Mantovani, Alberto

PY - 1996/4/1

Y1 - 1996/4/1

N2 - The aim of this study was to investigate the expression and release of the IL-1 type II decoy receptor (R) in mononuclear phagocytes, which play a central role in immune and chronic inflammatory reactions. Human monocytes expressed both type I and type II R transcripts, the latter being two- to threefold more represented. By cross-linking and Ab blocking, the predominant surface IL-1-binding molecule was the decoy RII. IL-4, IL-13, and dexamethasone induced RI and RII transcripts and augmented the number of IL- 1-binding sites with no modification of K(d) values. The induced surface receptor was identified as the decoy RII. These stimuli induced the release of a soluble R with a m.w. of approximately 60 kDa, of which N-glycosylation contributed 22 kDa compared with 45 kDa released from polymorphonuclear leukocytes, of which N-glycosylation contributed 15 kDa. IL-13 and dexamethasone induced a release of 24 ng/ml/2 x 107 cells (from 8.7 to 43.2 ng/ml) and 25.6 ng/ml/2 x 107 cells (from 9.7 to 36.8 ng/ml) of decoy RII in 18 h, respectively (six donors). Thus, for instance, IL-13-treated (18 h) cells expressed 3.5 x 103 sites/cell and released 12 x 103 decoy RII/cell. The released decoy RII from monocytes bound IL-1α and IL-1 receptor antagonist 30- and 2-fold less avidly than IL-1β, respectively. In vitro- matured, monocyte-derived macrophages showed higher levels of surface expression and release of the IL-1 decoy RII. The results show that, on exposure to diverse molecules with anti-inflammatory properties, mononuclear phagocytes express and release copious amounts of a novel version of the soluble IL-1 decoy RII.

AB - The aim of this study was to investigate the expression and release of the IL-1 type II decoy receptor (R) in mononuclear phagocytes, which play a central role in immune and chronic inflammatory reactions. Human monocytes expressed both type I and type II R transcripts, the latter being two- to threefold more represented. By cross-linking and Ab blocking, the predominant surface IL-1-binding molecule was the decoy RII. IL-4, IL-13, and dexamethasone induced RI and RII transcripts and augmented the number of IL- 1-binding sites with no modification of K(d) values. The induced surface receptor was identified as the decoy RII. These stimuli induced the release of a soluble R with a m.w. of approximately 60 kDa, of which N-glycosylation contributed 22 kDa compared with 45 kDa released from polymorphonuclear leukocytes, of which N-glycosylation contributed 15 kDa. IL-13 and dexamethasone induced a release of 24 ng/ml/2 x 107 cells (from 8.7 to 43.2 ng/ml) and 25.6 ng/ml/2 x 107 cells (from 9.7 to 36.8 ng/ml) of decoy RII in 18 h, respectively (six donors). Thus, for instance, IL-13-treated (18 h) cells expressed 3.5 x 103 sites/cell and released 12 x 103 decoy RII/cell. The released decoy RII from monocytes bound IL-1α and IL-1 receptor antagonist 30- and 2-fold less avidly than IL-1β, respectively. In vitro- matured, monocyte-derived macrophages showed higher levels of surface expression and release of the IL-1 decoy RII. The results show that, on exposure to diverse molecules with anti-inflammatory properties, mononuclear phagocytes express and release copious amounts of a novel version of the soluble IL-1 decoy RII.

UR - http://www.scopus.com/inward/record.url?scp=0029878510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029878510&partnerID=8YFLogxK

M3 - Article

C2 - 8786316

AN - SCOPUS:0029878510

VL - 156

SP - 2534

EP - 2541

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 7

ER -